A case of successful desensitization treatment with tepotinib after tepotinib-induced rash

A case of successful desensitization treatment with tepotinib after tepotinib-induced rash

Tepotinib is one of the key drugs for MET exon 14-skipping mutation-positive non-small cell lung cancer (NSCLC). The main adverse event of tepotinib treatment is edema. Rash is a rare adverse event, affecting only 0.7% of patients. We report a case of successful desensitization after skin rash cause...

Full description

Bibliographic Details
Main Authors: Tomoki Tamura, Sakura Hata, Takahiro Baba, Taisaku Koyanagi, Takahiro Umeno, Kazuya Nishii, Shoichi Kuyama
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Non-small cell lung cancer
Adverse event
Skin rash
Tepotinib
Desensitization
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007123001065

Internet

http://www.sciencedirect.com/science/article/pii/S2213007123001065

Similar Items